louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06408779: Study on Surgical Treatment Strategies for Moderate Ischemic Mitral Regurgitation
Official title: Study on Surgical Treatment Strategies for Moderate Ischemic Mitral Regurgitation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Mitral Valve Insufficiency
Mitral Valve Annuloplasty
Coronary Artery Bypass
Lead sponsor: China National Center for Cardiovascular Diseases
Sponsor class: OTHER_GOV
First posted: 2024-05-10
Enrollment: 464
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adult coronary artery disease patients complicated with moderate ischemic mitral regurgitation undergoing coronary artery bypass grafting with or without mitral valve repair from August 2009 to August 2023 were enrolled

Brief summary: This study aimed to compare the efficacy of isolated coronary artery bypass grafting and coronary artery bypass grafting + mitral valve repair in moderate ischemic mitral regurgitation patients through a cohort and explore the potential risk factors of the clinical outcomes.


Eligibility criteria: Inclusion Criteria:

1. Adult coronary artery disease patients complicated with moderate ischemic mitral regurgitation.
2. undergoing coronary artery bypass grafting with or without mitral valve repair.

Exclusion Criteria:

1. patients under the age of 18 years,
2. patients complicated with more than moderate ischemic mitral regurgitation or undergoing mitral valve replacement,
3. patients complicated with primary mitral valve disease other than ischemic mitral regurgitation, such as rheumatic mitral regurgitation or mitral valve leaflet prolapse,
4. patients undergoing concomitant aortic valve procedure.

Primary outcomes:
measure: major adverse cardiovascular and cerebrovascular events
timeFrame: 2years
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Study officials:
References:
Clinical trial NCT01665079: Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response
Official title: Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Obesity
Keywords: anaesthetics iv
propofol
pharmacokinetics
pharmacodynamic
Lead sponsor: Universidad del Desarrollo
Sponsor class: OTHER
First posted: 2012-08-15
Enrollment: 14
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this study is to characterize the Pharmacokinetic/Pharmacodynamic relationship of a single bolus dose of propofol in obese patients and to extract a time to peak effect (t-peak) from the estimated model parameters.

Detailed description: Target controlled infusion (TCI) is a technique to administer intravenous drugs that allows rapid achievement and maintenance of predetermined drug concentrations, either in plasma (Cp) or at the site of effect (Ce).

To characterize the time profile of propofol effect an additional parameter, the equilibration half time between plasma and effect site (T1/2keo) needs to be incorporated in the pharmacokinetic (PK) model.

Eligibility criteria: Inclusion Criteria:

* IMC \> 35 kg m-2
* Scheduled for laparoscopic bariatric surgery
* ASA I-II patients
* Between 20 and 60 yr of age.

Exclusion Criteria:

* Patients with allergy to study drugs
* Uncontrolled hypertension
* Heart block greater than first degree
* Take any drug acting in the central nervous system

Primary outcomes:
measure: Profile of Pharmacokinetic and Pharmacodynamic of an induction bolus dose of propofol in obese patients.
timeFrame: 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75
Secondary outcomes:
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Clinica Alemana
Study officials:
affiliation: Clinica Alemana Universidad del Desarrollo
name: Pablo O Sepúlveda, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cortinez LI, Sepulveda P, Rolle A, Cottin P, Guerrini A, Anderson BJ. Effect-Site Target-Controlled Infusion in the Obese: Model Derivation and Performance Assessment. Anesth Analg. 2018 Oct;127(4):865-872. doi: 10.1213/ANE.0000000000002814.
Clinical trial NCT00280579: Cyanide Poisoning in Fire Victims
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Carbon Monoxide Poisoning
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2006-01-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE

Brief summary: Aim: To determine the incidence of cyanide poisoning in fire victims.

20 consecutive patients will have the rest of their blood sample analyzed for cyanide.


Eligibility criteria: Inclusion Criteria:

* Age 18 years or older
* Exposed to smoke from fire and admitted to hospital

Exclusion Criteria:

None

Primary outcomes:
measure: Cyanide concentration
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Anaesthesia 4231, Centre of Head and Orthopaedics, Copenhagen University Hospital Rigshospitalet
Study officials:
affiliation: Department of anesthesia, 4231, Center of Head and Orthopaedics, Copenhagen University Hospital, Rigshospitalet
name: Erik C. Jansen, DMSC
role: STUDY_CHAIR
References:
citation: Lawson-Smith P, Jansen EC, Hilsted L, Hyldegaard O. Effect of hyperbaric oxygen therapy on whole blood cyanide concentrations in carbon monoxide intoxicated patients from fire accidents. Scand J Trauma Resusc Emerg Med. 2010 Jun 15;18:32. doi: 10.1186/1757-7241-18-32.
Clinical trial NCT00584779: An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis
Official title: An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: PK Properties Of Gabapentin In Subjects With Impaired Renal Function
Keywords: Gabapentin Pharmacokinetics, renal impairment
Lead sponsor: Pfizer
Sponsor class: INDUSTRY
First posted: 2008-01-02
Enrollment: 8
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To confirm the pharmacokinetics following administration of gabapentin to Japanese subjects with renal impairment, compare the results to Western study results and confirm the adaptive possibility of dose adjustment in US package insert to Japanese.

Detailed description: The study was terminated on September 30, 2008 at the current study site due to reported adverse events in the study subjects (n=8). While the adverse events reported were generally consistent with the known profile of gabapentin, it was decided that the study should continue at a different study site. The pharmacokinetics of gabapentin in the subjects with renal impairment will be evaluated in a separate study with a different study number at a different site. The study will be entitled: "The Pharmacokinetic Study of Gabapentin in Japanese Epileptic Subjects with Renal Impairment".

Eligibility criteria: Inclusion Criteria:

* The subjects whose creatinine clearance is 5-59 mL/min, or hemodialysis patients.
* The hemodialysis patients who enter this study is required hemodialysis for at least six weeks (the frequency is three times per week)

Exclusion Criteria:

* Renal allograft recipients

Primary outcomes:
measure: Pharmacokinetics
timeFrame: dec 2008
Secondary outcomes:
measure: There were no secondary outcomes measures for this study
timeFrame: dec 2008
Other outcomes:
Locations:
city: Aira-gun, Aira-cho
country: Japan
facility: Pfizer Investigational Site
state: Kagoshima-ken
Study officials:
affiliation: Pfizer
name: Pfizer CT.gov Call Center
role: STUDY_DIRECTOR
References:
Clinical trial NCT04613479: Frequency of Hepatobilliary Manifestations in Patients With Inflammatory Bowel Disease
Official title: Frequency of Hepatobilliary Manifestations in Patients With Inflammatory Bowel Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hepatobilliary Manifestations in Inflammatory Bowel Disease Patients
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2020-11-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients diagnosed IBD either crohns or ulcerative, male or female, age above 18 years old.

Brief summary: Hepatobilliary manifestations as extraintestinal manifestations of IBD are sometimes underdiagnosed which can impair patient prognosis

Detailed description: Non alcoholic fatty liver is aliver disease most commonly found in patient with IBD most commonly without intestinal activity.

On the other hand primary according cholangitis is the most common specific with IBD commonly with ulcerative colitis. and is commonly overlap with autoimmune hepatitis IBD therapy can also be a cause it can lead to hepatic toxicity and some drugs like ant TNF can cause hepatitis b virus activation.

Eligibility criteria: Inclusion Criteria:all patients diagnosed IBD crohns and ulcerative on conventional treatment and biological treatment -

Exclusion Criteria:no

-

Primary outcomes:
measure: The prevelance of hepatobilliary manifestations in IBD patients
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05428579: Status of Surgical Resection and Histologic Subtype as Predictors of Local Recurrence in Retroperitoneal Liposarcoma
Official title: Status of Surgical Resection and Histologic Subtype as Predictors of Local Recurrence in Retroperitoneal Liposarcoma - Case Series
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liposarcoma of Soft Tissue
Surgical Procedure, Unspecified
Keywords: retroperitoneal liposarcoma
overall survival
local recurrence free survival
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
First posted: 2022-06-23
Enrollment: 60
Sex: ALL
Minimum age (years): 17
Maximum age (years): 76
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 60 patients attended at the University of São Paulo Medical School Hospital (HC-FMUSP) and the Cancer Institute of the State of São Paulo (ICESP) from 1997 to 2017, who underwent surgical resection of the primary tumor at these institutions, as well as those referred after resection at other services.

Brief summary: Soft tissue sarcomas are rare malignant tumors. Liposarcoma constitute the most frequent histological subtype of retroperitoneal sarcoma. The prognosis of soft tissue sarcomas depend on clinical and histologic characteristics. Objective: Evaluate variables that may be related to overall survival and local recurrence free survival in patients with retroperitoneal liposarcoma. Methods: retrospective analysis of medical records of 60 patients attended from 1997 to 2017, who underwent surgical resection of retroperitoneal liposarcoma.


Eligibility criteria: Inclusion Criteria:

* All patients who underwent surgical resection of retroperitoneal liposarcoma

Exclusion Criteria:

* Unresectable disease (upper mesenteric artery or vein involvement) or metastatic disease (sarcomatosis or distant disease)

Primary outcomes:
measure: Overall survival rate
timeFrame: 60 months
measure: Local recurrence-free survival rate
timeFrame: 60 months
Secondary outcomes:
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Study officials:
References:
citation: Neuhaus SJ, Barry P, Clark MA, Hayes AJ, Fisher C, Thomas JM. Surgical management of primary and recurrent retroperitoneal liposarcoma. Br J Surg. 2005 Feb;92(2):246-52. doi: 10.1002/bjs.4802.
citation: Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1. doi: 10.1097/01.sla.0000086542.11899.38.
Clinical trial NCT06491979: Vitamin and Unsaturated Fatty Acid Supplements in Healthy and Uveitis Human Subjects
Official title: Interventional Study on the Treatment of Uveitis With Vitamin and Unsaturated Fatty Acid Combination Dietary Supplements Through Modulating T Cell Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Uveitis
Autoimmune Diseases
Lead sponsor: Tianjin Medical University
Sponsor class: OTHER
First posted: 2024-07-09
Enrollment: 7
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: The goal of this clinical trial is to learn if dietary supplements containing vitamin and unsaturated fatty acid works to intervene T cell inflammatory factor expression in patients with uveitis and healthy subjects in adults.


Eligibility criteria: Inclusion Criteria:

* healthy or with uveitis volunteers age 19-65 years.

Exclusion Criteria:

* abnormal blood glucose, blood pressure, blood lipids, or other systemic diseases should not participate in the study

Primary outcomes:
measure: Inflammatory factors-Interleukin-17A (IL-17A)
timeFrame: 3 weeks
measure: Inflammatory factors-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
timeFrame: 3 weeks
measure: Inflammatory factors-Interferon gamma (IFN-γ)
timeFrame: 3 weeks
Secondary outcomes:
measure: Cytokine levels-Interleukin-17A (IL-17A)
timeFrame: 3 weeks
measure: Cytokine levels-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
timeFrame: 3 weeks
measure: Cytokine levels-Interferon gamma (IFN-γ)
timeFrame: 3 weeks
measure: Cytokine levels-Interleukin-2 (IL-2)
timeFrame: 3 weeks
measure: Cytokine levels-Interleukin-10 (IL-10)
timeFrame: 3 weeks
measure: Cytokine levels-Interleukin-9 (IL-9)
timeFrame: 3 weeks
measure: Cytokine levels-Interleukin-4 (IL-4)
timeFrame: 3 weeks
measure: Cytokine levels-Tumor Necrosis Factor alpha (TNF-α)
timeFrame: 3 weeks
Other outcomes:
measure: Transcriptomics analysis
timeFrame: 3 weeks
measure: Proteomics analysis
timeFrame: 3 weeks
measure: post-translational modification proteomics analysis
timeFrame: 3 weeks
measure: metabolomics analysis
timeFrame: 3 weeks
Locations:
city: Tianjin
country: China
facility: Tianjin Medical University Eye Hospital
state: Tianjin
Study officials:
References:
Clinical trial NCT06853379: Aromatherapy Versus Diet
Official title: Aromatherapy Versus Diet Management on Children with Primary Nocturnal Enuresis
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Nocturnal Enuresis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-03-03
Enrollment: 30
Sex: ALL
Minimum age (years): 5
Maximum age (years): 10
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Eligible children were randomly divided into 2 groups assigned to receive dietary recommendations (group A) or to receive herbal compounds (group B). Children were treated for a period of one week , then cross over the two groups is done


Eligibility criteria: Inclusion Criteria:

* The participants age will be ranged from 5to 10 years.
* primary Nocturnal enuresis(NE) number of wet nights/week is more than 4\\7

Exclusion Criteria:

* secondary nocturnal enuresis to any neurological disorders , musculoskeletal problems, or congenital abnormalities
* the child receives any Pharmacological treatment to NE

Primary outcomes:
measure: number of wet days per week
timeFrame: ; for baseline evaluation of number of wet days per week, if the number is less than 4\7 the child will be excluded from the study. Second week; group A receives dietary recommendations , group B receives herbal compounds
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04384679: Benefit of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery
Official title: The Evaluation of Topical Hemostatic Powder Containing Hydrophilic Polymer With Potassium Ferrate for Hemostasis Following Nail Surgery
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Nail Diseases
Keywords: Nails
Nail Surgery
Hemostasis
Potassium Ferrate
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2020-05-12
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to assess the efficacy and safety of topical hemostatic powder containing hydrophilic polymer with potassium ferrate for bleeding control after nail surgical procedures


Eligibility criteria: Inclusion Criteria:

* At least 18 years old
* Patients scheduled for any type of nail surgical procedure
* Willingness to participate in the study
* Ability to understand all instructions in the English language

Exclusion Criteria:

* Failure to have nail surgery performed
* Likely inability to comply with the study protocol or cooperate fully with the research team

Primary outcomes:
measure: Time (in seconds) to bleeding cessation with hydrophilic polymer and potassium ferrate; time (in seconds) to bleeding cessation with direct pressure with sterile gauze
timeFrame: Baseline
Secondary outcomes:
measure: Number of participants with at least one adverse event
timeFrame: End of study (28 days)
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Cornell Medicine
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Shari R Lipner, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04839679: A Study to Evaluate Visually Inspired Patient Education Material on Willingness to Pursue Radiation Therapy
Official title: A Randomized Clinical Trial to Study the Utility of Visually Inspired Patient Education Material on Willingness to Pursue Radiation Therapy in American Indian and Alaska Native Individuals (VIEW Study)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Patient Education in Radiation Oncology
Keywords: Radiation therapy
Patient education
Radiation oncology
Native Americans
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-04-09
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: This research study is being done in order to better understand and identify American Indian/Alaskan Native (AI/AN) cancer patients' attitudes and beliefs towards radiation therapy treatment plans and their willingness to pursue them.


Eligibility criteria: Inclusion Criteria:

* Patient at least 18 years of age with cancer diagnosis.
* Radiation therapy is recommended for their cancer treatment as a next step in their cancer care.
* Cognitive capacity to complete a paper-and-pencil survey.
* Ability to communicate and understand English with proficiency to provide informed consent and complete a paper-and-pencil survey.

Exclusion Criteria:

* Patient \< 18 years of age.
* Patient does not have a cancer diagnosis.

Primary outcomes:
measure: Change in patient anxiety
timeFrame: Baseline, day 14
measure: Radiotherapy completion rates in the AI/AN community
timeFrame: 90 days
measure: Change in patient perception of information received
timeFrame: Baseline, day 14
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
Study officials:
affiliation: Mayo Clinic
name: Samir H. Patel, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03756584: Probing TBS-induced Neural Plasticity and Associated Effects on Learning
Official title: Probing TBS-induced Neural Plasticity and Associated Effects on Learning
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: The Hong Kong Polytechnic University
Sponsor class: OTHER
First posted: 2018-11-28
Enrollment: 75
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: single-blind parallel-group crossover design
Primary purpose: BASIC_SCIENCE

Brief summary: Recent animal research indicates that excitatory brain stimulation opens a time window of increased neural plasticity that permits remodeling of neural representations. Repetitive transcranial magnetic stimulation (rTMS) may thus facilitate learning of new associations by reducing proactive interference but human research is missing. Therefore, it is the aim of this study to investigate the effects of intermittent theta-burst stimulation (iTBS), a potent form of excitatory brain stimulation, on associative memory. Twenty right handed healthy participants will receive 3 minutes of iTBS or sham stimulation of the left lateral parietal cortex after memorizing a set of 20 face-word associations. Recall capacity will be tested directly before and after stimulation. Participants will then learn a new combination of associations using the same set of stimuli, followed by an evaluation of their recall capacity. It is hypothesized that iTBS compared to sham stimulation will reduce recall capacity directly after the stimulation but increase recall capacity of the newly learned associations due to reduced proactive interference. This study may not only pave the way towards a new understanding of the mechanism of action of brain stimulation, but can also help in developing new treatment strategies for neuropsychiatric disorders.


Eligibility criteria: Inclusion Criteria:

* education level of primary six or above
* right-handedness
* normal or corrected-to-normal vision

Exclusion Criteria:

* seizures in medical history
* current or past psychiatric disorders or severe internal or neurological illness
* common TMS exclusion criteria
* substance abuse or dependence
* intake of medication that is known to affect the excitation threshold

Primary outcomes:
measure: Change in recall capacity
timeFrame: Change from baseline to directly after stimulation (~6 min after baseline)
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: The Hong Kong Polytechnic University
Study officials:
affiliation: Department of Rehabilitation Sciences
name: Georg S Kranz, PhD
role: PRINCIPAL_INVESTIGATOR
References: